Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Oncternal Therapeutics Inc ONCT

Healthcare Biotechnology
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Company’s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of... see more

Recent & Breaking News (NDAQ:ONCT)

GTx Provides Corporate Update and Reports Fourth Quarter and Year-End 2014 Financial Results

Business Wire March 4, 2015

GTx, Inc. to Host Fourth Quarter and Full Year 2014 Financial Results Conference Call and Webcast

Business Wire February 19, 2015

GTx Appoints Robert J. Wills, Ph.D. to Board of Directors

Business Wire February 17, 2015

GTx to Present Results on Enobosarm 9mg in Women with Metastatic Breast Cancer at 2014 San Antonio Breast Cancer Symposium

Business Wire December 8, 2014

GTx Announces Closing of $43.4 Private Placement

Business Wire November 17, 2014

GTx Announces Webcast of Corporate Presentation at the Stifel 2014 Healthcare Conference

Business Wire November 12, 2014

GTx Provides Corporate Update and Reports Third Quarter 2014 Financial Results

Business Wire November 10, 2014

GTx Announces $43.4 Million Private Placement

Business Wire November 10, 2014

GTx, Inc. To Host Third Quarter 2014 Financial Results Conference Call and Webcast

Business Wire November 3, 2014

GTx Announces Webcast of Corporate Presentation at the 2014 Wedbush Pacgrow Life Sciences Management Access Conference

Business Wire August 7, 2014

GTx Provides Corporate Update and Reports Second Quarter 2014 Financial Results

Business Wire August 5, 2014

GTx, Inc. to Report Second Quarter 2014 Financial Results on August 5, 2014

Business Wire July 22, 2014

GTx Reports Positive Clinical Data from Open Label Phase 2 Study of Enobosarm in Patients with Androgen and Estrogen Receptor Positive Metastatic Breast Cancer

Business Wire June 2, 2014

GTx Announces Webcast of Corporate Presentation at Jefferies 2014 Global Healthcare Conference

Business Wire May 22, 2014

GTx to Present Clinical Data on Enobosarm in Breast Cancer and NSCLC at ASCO 2014 Annual Meeting

Business Wire May 19, 2014

GTx Provides Corporate Update and Reports First Quarter 2014 Financial Results

Business Wire May 8, 2014

GTx, Inc. To Report First Quarter 2014 Financial Results On May 8, 2014

Business Wire April 24, 2014

GTx Announces Departure of CEO

Business Wire April 4, 2014

GTx, Inc. Announces Closing of Private Placement

Business Wire March 6, 2014

GTx Announces Webcast of Corporate Presentation at 26TH Annual ROTH Conference

Business Wire March 5, 2014